20 hours ago
Medicare's two-year income lookback makes age 63 the last year a Roth conversion won't directly raise your Medicare premiums at 65.
Married couples can convert roughly $133,000 annually within the 22% bracket, but crossing the $218,000 IRMAA threshold triggers surcharges for both spouses.
Delaying Social Security to 70 preserves low-income years for conversions, since every dollar of benefits claimed adds an invisible marginal rate on top of conversion income.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
A 63-year-old with $1.4 million in a traditional 401(k) has a narrower Roth conversion window than the calendar suggests. Medicare enrollment at 65 uses a two-year lookback on modified adjusted gross income, which means the conversion executed at 63 is the one that sets Medicare premiums at 65. The real deadline arrives earlier than most people expect.
#income #roth #lookback
Married couples can convert roughly $133,000 annually within the 22% bracket, but crossing the $218,000 IRMAA threshold triggers surcharges for both spouses.
Delaying Social Security to 70 preserves low-income years for conversions, since every dollar of benefits claimed adds an invisible marginal rate on top of conversion income.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
A 63-year-old with $1.4 million in a traditional 401(k) has a narrower Roth conversion window than the calendar suggests. Medicare enrollment at 65 uses a two-year lookback on modified adjusted gross income, which means the conversion executed at 63 is the one that sets Medicare premiums at 65. The real deadline arrives earlier than most people expect.
#income #roth #lookback
22 hours ago
On September 15, Needham ***** yst James Ricchiuti lifted the firm's price target on Teledyne Technologies Incorporated (NYSE:TDY) to $760 from $750, and reiterated a Buy rating. The revised price target reflected an upside of 27% from the close of the note.
According to TipRanks, the ***** yst told investors that the company was well placed to gain from a broadening short cycle recovery and opportunities in modern defense applications. Needham further added that the stock offers a 2.6-to-1 risk/reward skew at current levels.
The adjustment is largely in line with the broader ***** yst community. As of the close on September 16, TDY is a Moderate Buy based on the consensus of 10 ***** ysts. It has a one-year average share price target of $758.20, representing an upside of 26%.
Needham noted 'broadening' improvements in the company's short cycle businesses, which suggests that momentum is spreading across product lines, rather than being limited to any one particular segment.
During the Q2 earnings call, the management noted that short-cycle commercial markets were beginning to show growth inflections after recent headwinds and lifted its short-cycle portfolio's growth outlook to mid-single-digits for the year, up from earlier estimates of flat to low-single-digit growth.
#cycle #september
According to TipRanks, the ***** yst told investors that the company was well placed to gain from a broadening short cycle recovery and opportunities in modern defense applications. Needham further added that the stock offers a 2.6-to-1 risk/reward skew at current levels.
The adjustment is largely in line with the broader ***** yst community. As of the close on September 16, TDY is a Moderate Buy based on the consensus of 10 ***** ysts. It has a one-year average share price target of $758.20, representing an upside of 26%.
Needham noted 'broadening' improvements in the company's short cycle businesses, which suggests that momentum is spreading across product lines, rather than being limited to any one particular segment.
During the Q2 earnings call, the management noted that short-cycle commercial markets were beginning to show growth inflections after recent headwinds and lifted its short-cycle portfolio's growth outlook to mid-single-digits for the year, up from earlier estimates of flat to low-single-digit growth.
#cycle #september
23 hours ago
CoinShares PLC (NASDAQ:CSHR) reported approximately $27.6 million in net inflows for the first half of 2026, yet U.S. GAAP revenue fell 35.7% to $51.4 million from $80 million. The September 14 results show that attracting **** ets and restoring earnings are different challenges.
Asset Management revenue declined to $40 million from $59.6 million. CoinShares PLC (NASDAQ:CSHR) attributed that decline primarily to lower average **** ets under management (AUM) following weaker digital-asset prices. Product mix and a targeted fee reduction add another hurdle: the revenue generated by each dollar of **** ets.
Positive flows during a difficult market provide evidence of demand. The physically backed product platform generated approximately $155.9 million in net inflows during the half. That suggests CoinShares PLC (NASDAQ:CSHR) can attract capital even when market performance reduces the value of existing holdings.
CoinShares PLC (NASDAQ:CSHR) reported that AUM recovered to approximately $6.93 billion by August 31 from $5.52 billion at June 30. Whether that recovery restores fee revenue depends on average **** ets and product mix.
A broader product mix also has strategic value. Lower-fee products may reach customers who would otherwise invest elsewhere. For CoinShares PLC (NASDAQ:CSHR), accepting a lower fee can make economic sense if it secures durable **** ets at an attractive cost.
#revenue
Asset Management revenue declined to $40 million from $59.6 million. CoinShares PLC (NASDAQ:CSHR) attributed that decline primarily to lower average **** ets under management (AUM) following weaker digital-asset prices. Product mix and a targeted fee reduction add another hurdle: the revenue generated by each dollar of **** ets.
Positive flows during a difficult market provide evidence of demand. The physically backed product platform generated approximately $155.9 million in net inflows during the half. That suggests CoinShares PLC (NASDAQ:CSHR) can attract capital even when market performance reduces the value of existing holdings.
CoinShares PLC (NASDAQ:CSHR) reported that AUM recovered to approximately $6.93 billion by August 31 from $5.52 billion at June 30. Whether that recovery restores fee revenue depends on average **** ets and product mix.
A broader product mix also has strategic value. Lower-fee products may reach customers who would otherwise invest elsewhere. For CoinShares PLC (NASDAQ:CSHR), accepting a lower fee can make economic sense if it secures durable **** ets at an attractive cost.
#revenue
1 day ago
Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) reported a widening split between dining and entertainment in its September 14 second-quarter results. Food-and-beverage revenue increased to $211.5 million from $192.9 million, while entertainment revenue fell to $332.6 million from $364.5 million.
For the fiscal quarter ended August 4, 2026, total revenue declined 2.4% to $544.1 million. Operating income dropped to $19.4 million from $53 million. The GAAP net loss was $12.5 million, versus net income of $11.4 million a year earlier. Stronger restaurant sales are providing support, but the investment question is whether they can also bring customers back to the games.
Food-and-beverage revenue grew approximately 9.6%, giving Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) an identifiable source of momentum. A more appealing dining experience could encourage repeat visits, group occasions, and longer stays, creating additional opportunities to sell entertainment.
Management reported ongoing growth in food-and-beverage and special-events sales, alongside improving comparable-sales trends in July and the third quarter to date. That suggests the recovery effort has some traction beyond a single revenue category, although the later sales improvement was not quantified.
Management also said remodeled locations continued to outperform the system on comparable sales. That supports selective investment in existing venues, provided the additional revenue earns adequate returns on remodeling costs.
#entertainment #dave
For the fiscal quarter ended August 4, 2026, total revenue declined 2.4% to $544.1 million. Operating income dropped to $19.4 million from $53 million. The GAAP net loss was $12.5 million, versus net income of $11.4 million a year earlier. Stronger restaurant sales are providing support, but the investment question is whether they can also bring customers back to the games.
Food-and-beverage revenue grew approximately 9.6%, giving Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) an identifiable source of momentum. A more appealing dining experience could encourage repeat visits, group occasions, and longer stays, creating additional opportunities to sell entertainment.
Management reported ongoing growth in food-and-beverage and special-events sales, alongside improving comparable-sales trends in July and the third quarter to date. That suggests the recovery effort has some traction beyond a single revenue category, although the later sales improvement was not quantified.
Management also said remodeled locations continued to outperform the system on comparable sales. That supports selective investment in existing venues, provided the additional revenue earns adequate returns on remodeling costs.
#entertainment #dave
1 day ago
Exodus Movement, Inc. (NYSEAMERICAN:EXOD) reported on September 11 that August payment-processing gross transaction volume reached $356.8 million, up from $338.0 million in July. Monthly active cards declined to 757,900 from 783,600.
Separately, Web3 exchange-provider processed volume increased to $376.8 million from $314.8 million, while reported monthly active users remained at 1.4 million. The figures show stronger transaction activity alongside fewer active cards and a stable reported user count.
The question is whether that activity produces enough revenue to improve profitability while Exodus Movement, Inc. (NYSEAMERICAN:EXOD) integrates Monavate and reduces costs.
Payment growth persists after adjusting for currency translation. Exodus Movement, Inc. (NYSEAMERICAN:EXOD) converted sterling payment volumes into dollars using average rates of $1.35 per pound for August and $1.34 for July. Reversing those conversions implies approximately 4.8% growth in underlying sterling volume, compared with 5.6% in reported dollars. Both calculations use rounded disclosed figures.
Web3 exchange-provider volume increased approximately 19.7%. XO Swap partners contributed 23% of volume in both months. The unchanged reported share suggests both the partner channel and the remaining business contributed to growth.
#reported #exodus #nyseamerican
Separately, Web3 exchange-provider processed volume increased to $376.8 million from $314.8 million, while reported monthly active users remained at 1.4 million. The figures show stronger transaction activity alongside fewer active cards and a stable reported user count.
The question is whether that activity produces enough revenue to improve profitability while Exodus Movement, Inc. (NYSEAMERICAN:EXOD) integrates Monavate and reduces costs.
Payment growth persists after adjusting for currency translation. Exodus Movement, Inc. (NYSEAMERICAN:EXOD) converted sterling payment volumes into dollars using average rates of $1.35 per pound for August and $1.34 for July. Reversing those conversions implies approximately 4.8% growth in underlying sterling volume, compared with 5.6% in reported dollars. Both calculations use rounded disclosed figures.
Web3 exchange-provider volume increased approximately 19.7%. XO Swap partners contributed 23% of volume in both months. The unchanged reported share suggests both the partner channel and the remaining business contributed to growth.
#reported #exodus #nyseamerican
2 days ago
The broader benchmark S&P 500 (SNPINDEX:^GSPC) has seemingly hit a wall over the past month, down about 2.3%.
On the whole, the S&P 500 is still having a decent year, but considering the Iran war and high inflation expectations, among other concerns, it's not hard to see why investors and market strategists have grown concerned.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Recently, one of Wall Street's most bullish strategists trimmed his S&P 500 price target for the year.
Ed Yardeni of Yardeni Research recently slashed his forecast from 8,400 to 7,900, which suggests minimal upside in the final 3.5 months of the year, with the index already around 7,600. 8,400 had been the highest price target on the Street.
#yardeni #recently #price
On the whole, the S&P 500 is still having a decent year, but considering the Iran war and high inflation expectations, among other concerns, it's not hard to see why investors and market strategists have grown concerned.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Recently, one of Wall Street's most bullish strategists trimmed his S&P 500 price target for the year.
Ed Yardeni of Yardeni Research recently slashed his forecast from 8,400 to 7,900, which suggests minimal upside in the final 3.5 months of the year, with the index already around 7,600. 8,400 had been the highest price target on the Street.
#yardeni #recently #price
2 days ago
On September 14, Radiant Logistics (NYSEAMERICAN:RLGT) held its fourth fiscal quarter earnings call, and the headline numbers landed harder than a typical logistics update. Net income jumped 53.1% to $7.5 million for the quarter ended June 30, while revenue climbed 18.5% to $261.4 million. Look past that one quarter, though, and the picture gets more complicated, because full-year adjusted profitability actually fell. That gap between a blowout quarter and a softer year is what makes this name worth a closer look.
The fourth fiscal quarter was strong from top to bottom. Adjusted EBITDA rose 31.6% to $10.4 million, margin expanded 240 basis points to 15.5%, and adjusted net income climbed 34.5% to $7.4 million, all against organic revenue growth of 8%. Management credited the acceleration to US forwarding operations and international airfreight, including work supporting disaster relief after typhoon activity hit the Western Pacific earlier this year, plus airfreight demand tied to capital flows into global data center buildouts.
The balance sheet backs up the story. Radiant enters fiscal 2027 with zero net debt, $25.6 million in cash as of June 30, and a $200 million senior credit facility that was extended and restated in August, pushing maturity out to August 7, 2031, while its acquisition-focused accordion grew to $100 million from $75 million. On the domestic side, capacity has been exiting the truckload and intermodal markets, and spot rates and tender rejections moved higher late in the quarter. Radiant also launched a new independent agent program at Radiant Road & Rail during the quarter, extending its freight forwarding agent network into truck brokerage and intermodal, while Navegate is gaining traction, with one enterprise customer now managing more than 1,400 vendors on the platform.
The full-year numbers tell a different story than the quarter does. Revenue rose just 3.5% to $934.4 million from $902.7 million, a fraction of the fourth quarter's 18.5% pace, and full-year net income grew a modest 8.7% to $18.8 million. Full-year adjusted EBITDA actually fell 5.4% to $36.7 million from $38.8 million, and that figure included a $1.3 million First Brands adjustment. Strip that out and normalized adjusted EBITDA comes in at $35.4 million, an even steeper decline than the headline number suggests.
The operating backdrop stays complicated too. Ocean shipping routes remain disrupted by the closure of the Strait of Hormuz and continued Houthi activity affecting Suez Canal transits, keeping capacity tight on key trade lanes. US tariff policy is generating elevated IEEPA-related filing activity, and Canada put new retaliatory tariff measures into effect in early September, adding fresh complexity for shippers moving goods across that border. Management itself acknowledged that the domestic truck brokerage improvement seen late in the fourth quarter is not yet fully reflected in the reported results.
#quarter #revenue
The fourth fiscal quarter was strong from top to bottom. Adjusted EBITDA rose 31.6% to $10.4 million, margin expanded 240 basis points to 15.5%, and adjusted net income climbed 34.5% to $7.4 million, all against organic revenue growth of 8%. Management credited the acceleration to US forwarding operations and international airfreight, including work supporting disaster relief after typhoon activity hit the Western Pacific earlier this year, plus airfreight demand tied to capital flows into global data center buildouts.
The balance sheet backs up the story. Radiant enters fiscal 2027 with zero net debt, $25.6 million in cash as of June 30, and a $200 million senior credit facility that was extended and restated in August, pushing maturity out to August 7, 2031, while its acquisition-focused accordion grew to $100 million from $75 million. On the domestic side, capacity has been exiting the truckload and intermodal markets, and spot rates and tender rejections moved higher late in the quarter. Radiant also launched a new independent agent program at Radiant Road & Rail during the quarter, extending its freight forwarding agent network into truck brokerage and intermodal, while Navegate is gaining traction, with one enterprise customer now managing more than 1,400 vendors on the platform.
The full-year numbers tell a different story than the quarter does. Revenue rose just 3.5% to $934.4 million from $902.7 million, a fraction of the fourth quarter's 18.5% pace, and full-year net income grew a modest 8.7% to $18.8 million. Full-year adjusted EBITDA actually fell 5.4% to $36.7 million from $38.8 million, and that figure included a $1.3 million First Brands adjustment. Strip that out and normalized adjusted EBITDA comes in at $35.4 million, an even steeper decline than the headline number suggests.
The operating backdrop stays complicated too. Ocean shipping routes remain disrupted by the closure of the Strait of Hormuz and continued Houthi activity affecting Suez Canal transits, keeping capacity tight on key trade lanes. US tariff policy is generating elevated IEEPA-related filing activity, and Canada put new retaliatory tariff measures into effect in early September, adding fresh complexity for shippers moving goods across that border. Management itself acknowledged that the domestic truck brokerage improvement seen late in the fourth quarter is not yet fully reflected in the reported results.
#quarter #revenue
2 days ago
Alluvium ******* et Management, an ******* et management company, released its "Conventum – Alluvium Global Fund" second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined 1.4% in EUR terms, 2.2% in USD terms, and 3.9% in AUD terms. Portfolio results were mixed, with Alphabet benefiting from strong Cloud growth, while Robert Half, H&R Block, and other holdings posted solid gains. However, cable businesses and several healthcare and consumer holdings weighed on performance. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Conventum – Alluvium Global Fund highlighted Robert Half Inc. (NYSE:RHI). Robert Half Inc. (NYSE:RHI) is a leading staffing and consulting company. On September 15, 2026, Robert Half Inc. (NYSE:RHI) closed at $38.30 per share. Over the past month, Robert Half Inc. (NYSE:RHI) declined 12.03% and its shares gained 10.28% over the past 52 weeks. Robert Half Inc. (NYSE:RHI) has a market capitalization of $3.92 billion, and its stock has traded within a 52-week range of $21.83 and $46.70.
Conventum – Alluvium Global Fund stated the following regarding Robert Half Inc. (NYSE:RHI) in its Q2 2026 investor letter:
"We last wrote about Robert Half Inc. (NYSE:RHI) (up 23.5%) in our December report, where we mentioned that hindsight suggests our purchasing during price descents in May, August and October were mistakes. This remains the case - but less so. Our expectation that the recruitment / outplacement market will slowly recover, appears, going by Robert Half's recent results, to be bearing fruit. And management remain cautiously optimistic. We did not trade the stock. The Fund's position is now 2.7%."
Robert Half Inc. (NYSE:RHI) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Robert Half Inc. (NYSE:RHI) at the end of the second quarter which was 36 in the previous quarter. While we acknowledge the potential of Robert Half Inc. (NYSE:RHI) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#half #NYSE
In its second-quarter 2026 investor letter, Conventum – Alluvium Global Fund highlighted Robert Half Inc. (NYSE:RHI). Robert Half Inc. (NYSE:RHI) is a leading staffing and consulting company. On September 15, 2026, Robert Half Inc. (NYSE:RHI) closed at $38.30 per share. Over the past month, Robert Half Inc. (NYSE:RHI) declined 12.03% and its shares gained 10.28% over the past 52 weeks. Robert Half Inc. (NYSE:RHI) has a market capitalization of $3.92 billion, and its stock has traded within a 52-week range of $21.83 and $46.70.
Conventum – Alluvium Global Fund stated the following regarding Robert Half Inc. (NYSE:RHI) in its Q2 2026 investor letter:
"We last wrote about Robert Half Inc. (NYSE:RHI) (up 23.5%) in our December report, where we mentioned that hindsight suggests our purchasing during price descents in May, August and October were mistakes. This remains the case - but less so. Our expectation that the recruitment / outplacement market will slowly recover, appears, going by Robert Half's recent results, to be bearing fruit. And management remain cautiously optimistic. We did not trade the stock. The Fund's position is now 2.7%."
Robert Half Inc. (NYSE:RHI) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Robert Half Inc. (NYSE:RHI) at the end of the second quarter which was 36 in the previous quarter. While we acknowledge the potential of Robert Half Inc. (NYSE:RHI) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#half #NYSE
2 days ago
This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter.
Is there a disconnect between finance teams and procurement teams? A new survey of 2,005 procurement leaders in the U.S. and the U.K. suggests there is for some companies, and it may ultimately be affecting their bottom lines.
Released Tuesday, the report from California-based contract lifecycle management company Agiloft showed that about one in 10 respondents said they have no shared metrics between chief procurement officers and CFOs. The lack of shared metrics was cited among the biggest obstacles preventing companies from "closing the gap between what procurement negotiates and what finance realizes."
Other barriers cited were lack of contract data visibility, selected by 14% of respondents, along with manual processes that create exceptions that go unseen (23%).
Agiloft's survey included responses gathered from 2,005 chief procurement officers and other procurement leaders Aug. 5-20.
#procurement
Is there a disconnect between finance teams and procurement teams? A new survey of 2,005 procurement leaders in the U.S. and the U.K. suggests there is for some companies, and it may ultimately be affecting their bottom lines.
Released Tuesday, the report from California-based contract lifecycle management company Agiloft showed that about one in 10 respondents said they have no shared metrics between chief procurement officers and CFOs. The lack of shared metrics was cited among the biggest obstacles preventing companies from "closing the gap between what procurement negotiates and what finance realizes."
Other barriers cited were lack of contract data visibility, selected by 14% of respondents, along with manual processes that create exceptions that go unseen (23%).
Agiloft's survey included responses gathered from 2,005 chief procurement officers and other procurement leaders Aug. 5-20.
#procurement
3 days ago
Fed Chair Kevin Warsh used his Aug. 28 keynote speech at Jackson Hole to drive home the point that inflation is broader than the headline rate suggests, speaking directly to the everyday experiences of a rising price level that most people have been having for a while now. Specifically, Warsh said 54% of the 199 items in the personal consumption expenditures (PCE) price index, which is the Fed's preferred inflation gauge, had risen by more than 3% in the 12 months through summer 2026, versus 32% of those items in the two decades before the pandemic.
That's a bit of an awkward situation for the companies that make up the S&P 500 (SNPINDEX: ^GSPC), whose stellar growth in 2026 has been built on profits that are much higher than average. In short, the next thing the market will need to deal with is, in all probability, a Federal Reserve that's keen on making businesses pay more for each dollar of borrowing, which could in turn end up leading to investors paying less for each dollar of profit ***** ociated with the ***** ets they buy.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's how that could unfold, and soon.
After the Sept. 11 inflation report showed that consumer prices are still rising at a faster-than-desired pace, the odds of a rate hike by the Fed at its meeting on Sept. 16 were 90%, per the CME FedWatch. Warsh also said in his speech that he'd struggle to call the current set of financial conditions restrictive. That obviously means that investors need to brace for higher rates.
#inflation
That's a bit of an awkward situation for the companies that make up the S&P 500 (SNPINDEX: ^GSPC), whose stellar growth in 2026 has been built on profits that are much higher than average. In short, the next thing the market will need to deal with is, in all probability, a Federal Reserve that's keen on making businesses pay more for each dollar of borrowing, which could in turn end up leading to investors paying less for each dollar of profit ***** ociated with the ***** ets they buy.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Here's how that could unfold, and soon.
After the Sept. 11 inflation report showed that consumer prices are still rising at a faster-than-desired pace, the odds of a rate hike by the Fed at its meeting on Sept. 16 were 90%, per the CME FedWatch. Warsh also said in his speech that he'd struggle to call the current set of financial conditions restrictive. That obviously means that investors need to brace for higher rates.
#inflation
3 days ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
3 days ago
Citigroup Inc. (NYSE:C)'s CFO Gonzalo Luchetti said the bank expects return on tangible common equity (RoTCE) to come in slightly above 11% in 2026, while also indicating that Citi will increase stock buybacks from the $13 billion repurchased in 2025. The bank plans to accelerate roughly $500 million of investment by year-end, including spending on severance and marketing intended to expand its credit-card and wealth-management businesses. Citi also expects to remove Banamex from its balance sheet in 2027, which will create an estimated $9 billion currency-translation adjustment loss.
The 11%+ target is meaningful because Citi's profitability has already improved materially. In the second quarter, Citi generated $24.8 billion of revenue, up 14% year over year, while net income rose 45% to $5.8 billion. Investment-banking revenue increased 44% to $1.55 billion, and net interest income increased 13%. Citi's SEC filing shows second-quarter RoTCE of 13.0%, versus 8.7% a year earlier, while the first half of 2026 produced a 13.1% RoTCE. The new guidance therefore suggests management believes profitability can remain above the longer-term 11%-13% RoTCE range Citi established for 2027-28, despite additional investment spending.
Kiev.Victor / Shutterstock.com
The bullish argument is that Citigroup Inc. (NYSE:C) appears to be converting its multiyear restructuring into higher returns while simultaneously returning more capital to shareholders. The move from 8.7% RoTCE in the second quarter of 2025 to 13.0% in the second quarter of 2026 represents a substantial improvement in capital efficiency. Citi's efficiency ratio also improved to 57.4% from 62.7%, indicating that revenue growth is increasingly translating into operating leverage rather than being absorbed by expenses. That is particularly relevant because management now intends to spend another roughly $500 million on severance, marketing, and growth initiatives; if these investments produce the intended expansion in cards and wealth management, they could support revenue growth without derailing the profitability trajectory.
Capital returns provide another positive lever. Citi repurchased $13 billion of stock in 2025 and now expects to increase that amount, while its June 2026 CET1 ratio remained 12.78%, comfortably above its 11.6% standardized regulatory requirement. Buybacks can reduce tangible common equity and shares outstanding, potentially supporting both RoTCE and per-share earnings when executed below intrinsic value. Citi's tangible book value per share had already risen 7% year over year to $100.89 by June 30, 2026. The combination of higher operating profitability, shrinking share count, and improving capital efficiency strengthens the case for a valuation re-rating if Citi can sustain returns above 11%.
#rotce #citi #management
The 11%+ target is meaningful because Citi's profitability has already improved materially. In the second quarter, Citi generated $24.8 billion of revenue, up 14% year over year, while net income rose 45% to $5.8 billion. Investment-banking revenue increased 44% to $1.55 billion, and net interest income increased 13%. Citi's SEC filing shows second-quarter RoTCE of 13.0%, versus 8.7% a year earlier, while the first half of 2026 produced a 13.1% RoTCE. The new guidance therefore suggests management believes profitability can remain above the longer-term 11%-13% RoTCE range Citi established for 2027-28, despite additional investment spending.
Kiev.Victor / Shutterstock.com
The bullish argument is that Citigroup Inc. (NYSE:C) appears to be converting its multiyear restructuring into higher returns while simultaneously returning more capital to shareholders. The move from 8.7% RoTCE in the second quarter of 2025 to 13.0% in the second quarter of 2026 represents a substantial improvement in capital efficiency. Citi's efficiency ratio also improved to 57.4% from 62.7%, indicating that revenue growth is increasingly translating into operating leverage rather than being absorbed by expenses. That is particularly relevant because management now intends to spend another roughly $500 million on severance, marketing, and growth initiatives; if these investments produce the intended expansion in cards and wealth management, they could support revenue growth without derailing the profitability trajectory.
Capital returns provide another positive lever. Citi repurchased $13 billion of stock in 2025 and now expects to increase that amount, while its June 2026 CET1 ratio remained 12.78%, comfortably above its 11.6% standardized regulatory requirement. Buybacks can reduce tangible common equity and shares outstanding, potentially supporting both RoTCE and per-share earnings when executed below intrinsic value. Citi's tangible book value per share had already risen 7% year over year to $100.89 by June 30, 2026. The combination of higher operating profitability, shrinking share count, and improving capital efficiency strengthens the case for a valuation re-rating if Citi can sustain returns above 11%.
#rotce #citi #management
3 days ago
Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use.
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and **** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.
#patients #weight #c
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and **** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.
#patients #weight #c
3 days ago
Kimberly-Clark Corporation (NASDAQ:KMB) is preparing **** et sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in Australia, where the deal received conditional approval after Kimberly-Clark agreed to divest Kenvue's Carefree and Stayfree brands.
The transaction is strategically important because it would create a consumer-health and personal-care company with approximately $32 billion of annual revenue and $7 billion of adjusted EBITDA. Kimberly-Clark Corporation (NASDAQ:KMB) expects about $1.9 billion of annual cost synergies and $500 million of revenue synergies, although it expects to invest roughly $2.5 billion in cash to achieve the cost savings. Therefore, the scale of any EU divestitures will be critical to determining whether Kimberly-Clark can retain the expected economic benefits of the deal.
The strongest bullish argument is that Kimberly-Clark Corporation (NASDAQ:KMB) is actively working toward a regulatory solution rather than allowing the EU review to threaten the transaction. If the company can satisfy regulators through limited **** et sales, it could preserve the majority of Kenvue's revenue and earnings while moving ahead with the combination. The expected $1.9 billion in annual cost savings represents a substantial earnings opportunity relative to the combined company's roughly $7 billion adjusted EBITDA target, giving Kimberly-Clark significant potential to improve margins and cash generation after integration.
The Australian precedent also suggests that targeted divestitures could be sufficient to resolve competition concerns without materially undermining the broader deal. Securing EU approval by September 29 would be particularly positive because it would remove a major source of uncertainty and allow Kimberly-Clark Corporation (NASDAQ:KMB) to focus on integration and synergy execution. With Kenvue adding major brands across consumer health and personal care, successful completion could also broaden Kimberly-Clark's portfolio and reduce its reliance on its existing product categories.
The biggest risk is that the EU requires more substantial **** et sales than Kimberly-Clark Corporation (NASDAQ:KMB) currently expects. Giving up attractive Kenvue brands or businesses in Europe could reduce the revenue and EBITDA acquired through the transaction, while Kimberly-Clark would still have to bear much of the financing, transaction, and integration burden. That could make the $40 billion purchase price less attractive on a risk-adjusted basis, particularly if the divested **** ets are among Kenvue's stronger European businesses.
#kimberly #revenue #ebitda
The transaction is strategically important because it would create a consumer-health and personal-care company with approximately $32 billion of annual revenue and $7 billion of adjusted EBITDA. Kimberly-Clark Corporation (NASDAQ:KMB) expects about $1.9 billion of annual cost synergies and $500 million of revenue synergies, although it expects to invest roughly $2.5 billion in cash to achieve the cost savings. Therefore, the scale of any EU divestitures will be critical to determining whether Kimberly-Clark can retain the expected economic benefits of the deal.
The strongest bullish argument is that Kimberly-Clark Corporation (NASDAQ:KMB) is actively working toward a regulatory solution rather than allowing the EU review to threaten the transaction. If the company can satisfy regulators through limited **** et sales, it could preserve the majority of Kenvue's revenue and earnings while moving ahead with the combination. The expected $1.9 billion in annual cost savings represents a substantial earnings opportunity relative to the combined company's roughly $7 billion adjusted EBITDA target, giving Kimberly-Clark significant potential to improve margins and cash generation after integration.
The Australian precedent also suggests that targeted divestitures could be sufficient to resolve competition concerns without materially undermining the broader deal. Securing EU approval by September 29 would be particularly positive because it would remove a major source of uncertainty and allow Kimberly-Clark Corporation (NASDAQ:KMB) to focus on integration and synergy execution. With Kenvue adding major brands across consumer health and personal care, successful completion could also broaden Kimberly-Clark's portfolio and reduce its reliance on its existing product categories.
The biggest risk is that the EU requires more substantial **** et sales than Kimberly-Clark Corporation (NASDAQ:KMB) currently expects. Giving up attractive Kenvue brands or businesses in Europe could reduce the revenue and EBITDA acquired through the transaction, while Kimberly-Clark would still have to bear much of the financing, transaction, and integration burden. That could make the $40 billion purchase price less attractive on a risk-adjusted basis, particularly if the divested **** ets are among Kenvue's stronger European businesses.
#kimberly #revenue #ebitda
3 days ago
Citi has begun coverage of the newly listed The Magnum Ice Cream Company (EURONEXT:MICC, LSE:MICC, NYSE:MICC) with a lukewarm "neutral" rating, warning that the maker of the eponymous chocolate-coated lollies faces a tougher year ahead after a **** per summer.
The broker set a target price of €17.7 on the shares, arguing that kind weather and solid delivery on cost cuts have already pushed Magnum's valuation up to broadly match its European food peers, leaving little room for further gains.
Citi's central doubt is whether the good times can last. A durable re-rating, it said, takes more than one strong season, and history suggests companies leaning on cost-saving stories rarely hold on to lofty valuations for long.
Several clouds loom over next year. The broker flagged the risk that El Niño weather patterns push up ingredient costs in the second half of 2027, which could expose how sensitive take-home ice cream sales are to price rises.
It also cited the spread of GLP-1 weight-loss drugs as a potential drag on demand, alongside the usual uncertainty over weather comparisons.
#micc #year
The broker set a target price of €17.7 on the shares, arguing that kind weather and solid delivery on cost cuts have already pushed Magnum's valuation up to broadly match its European food peers, leaving little room for further gains.
Citi's central doubt is whether the good times can last. A durable re-rating, it said, takes more than one strong season, and history suggests companies leaning on cost-saving stories rarely hold on to lofty valuations for long.
Several clouds loom over next year. The broker flagged the risk that El Niño weather patterns push up ingredient costs in the second half of 2027, which could expose how sensitive take-home ice cream sales are to price rises.
It also cited the spread of GLP-1 weight-loss drugs as a potential drag on demand, alongside the usual uncertainty over weather comparisons.
#micc #year
3 days ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
3 days ago
The aerospace industry is evolving as Boeing (NYSE:BA) attempts a massive operational turnaround while Rocket Lab (NASDAQ:RKLB) rapidly expands its footprint across the global ******* e economy.
Boeing remains a dominant force in commercial aviation and defense, whereas Rocket Lab specializes in small-satellite launches and ******* ecraft components. Investors often compare them to decide between an established giant recovering from crisis and a high-growth challenger in the private ******* e sector.
Boeing operates as a massive player among defense stocks and commercial aviation leaders, manufacturing everything from the 737 Max to advanced military rotorcraft. The company generates revenue through commercial aircraft sales, defense contracts with the U.S. Department of Defense and NASA, and global services. Customer concentration like this adds a layer of risk to the business. In 2025, the company acquired Spirit AeroSystems to address long-standing quality issues, providing transition services to other buyers like Airbus (OTC:EADSF).
In FY 2025, revenue reached nearly $89.5 billion, representing a growth of roughly 34.5% over the previous year. The company reported a net income of approximately $2.2 billion, a significant recovery from the net loss of nearly $11.8 billion in FY 2024. This improvement in the net margin to 2.5% suggests the company is beginning to stabilize its bottom line after years of heavy losses.
As of its December 2025 balance sheet, Boeing carries a debt-to-equity ratio of nearly 10.0x, a measure comparing total debt to shareholder equity that indicates a heavy reliance on borrowing. The company reported a current ratio of nearly 1.2x, which measures a company's ability to cover its short-term debts with liquid ******* ets. Note that stock-based compensation represented roughly 40% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement. The company also generated a negative free cash flow of approximately $1.9 billion, representing operating cash minus spending on physical ******* ets.
#boeing #nearly #rocket
Boeing remains a dominant force in commercial aviation and defense, whereas Rocket Lab specializes in small-satellite launches and ******* ecraft components. Investors often compare them to decide between an established giant recovering from crisis and a high-growth challenger in the private ******* e sector.
Boeing operates as a massive player among defense stocks and commercial aviation leaders, manufacturing everything from the 737 Max to advanced military rotorcraft. The company generates revenue through commercial aircraft sales, defense contracts with the U.S. Department of Defense and NASA, and global services. Customer concentration like this adds a layer of risk to the business. In 2025, the company acquired Spirit AeroSystems to address long-standing quality issues, providing transition services to other buyers like Airbus (OTC:EADSF).
In FY 2025, revenue reached nearly $89.5 billion, representing a growth of roughly 34.5% over the previous year. The company reported a net income of approximately $2.2 billion, a significant recovery from the net loss of nearly $11.8 billion in FY 2024. This improvement in the net margin to 2.5% suggests the company is beginning to stabilize its bottom line after years of heavy losses.
As of its December 2025 balance sheet, Boeing carries a debt-to-equity ratio of nearly 10.0x, a measure comparing total debt to shareholder equity that indicates a heavy reliance on borrowing. The company reported a current ratio of nearly 1.2x, which measures a company's ability to cover its short-term debts with liquid ******* ets. Note that stock-based compensation represented roughly 40% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement. The company also generated a negative free cash flow of approximately $1.9 billion, representing operating cash minus spending on physical ******* ets.
#boeing #nearly #rocket
3 days ago
Citigroup Inc. (NYSE:C)'s CFO Gonzalo Luchetti said the bank expects return on tangible common equity (RoTCE) to come in slightly above 11% in 2026, while also indicating that Citi will increase stock buybacks from the $13 billion repurchased in 2025. The bank plans to accelerate roughly $500 million of investment by year-end, including spending on severance and marketing intended to expand its credit-card and wealth-management businesses. Citi also expects to remove Banamex from its balance sheet in 2027, which will create an estimated $9 billion currency-translation adjustment loss.
The 11%+ target is meaningful because Citi's profitability has already improved materially. In the second quarter, Citi generated $24.8 billion of revenue, up 14% year over year, while net income rose 45% to $5.8 billion. Investment-banking revenue increased 44% to $1.55 billion, and net interest income increased 13%. Citi's SEC filing shows second-quarter RoTCE of 13.0%, versus 8.7% a year earlier, while the first half of 2026 produced a 13.1% RoTCE. The new guidance therefore suggests management believes profitability can remain above the longer-term 11%-13% RoTCE range Citi established for 2027-28, despite additional investment spending.
Kiev.Victor / Shutterstock.com
The bullish argument is that Citigroup Inc. (NYSE:C) appears to be converting its multiyear restructuring into higher returns while simultaneously returning more capital to shareholders. The move from 8.7% RoTCE in the second quarter of 2025 to 13.0% in the second quarter of 2026 represents a substantial improvement in capital efficiency. Citi's efficiency ratio also improved to 57.4% from 62.7%, indicating that revenue growth is increasingly translating into operating leverage rather than being absorbed by expenses. That is particularly relevant because management now intends to spend another roughly $500 million on severance, marketing, and growth initiatives; if these investments produce the intended expansion in cards and wealth management, they could support revenue growth without derailing the profitability trajectory.
Capital returns provide another positive lever. Citi repurchased $13 billion of stock in 2025 and now expects to increase that amount, while its June 2026 CET1 ratio remained 12.78%, comfortably above its 11.6% standardized regulatory requirement. Buybacks can reduce tangible common equity and shares outstanding, potentially supporting both RoTCE and per-share earnings when executed below intrinsic value. Citi's tangible book value per share had already risen 7% year over year to $100.89 by June 30, 2026. The combination of higher operating profitability, shrinking share count, and improving capital efficiency strengthens the case for a valuation re-rating if Citi can sustain returns above 11%.
#year #management
The 11%+ target is meaningful because Citi's profitability has already improved materially. In the second quarter, Citi generated $24.8 billion of revenue, up 14% year over year, while net income rose 45% to $5.8 billion. Investment-banking revenue increased 44% to $1.55 billion, and net interest income increased 13%. Citi's SEC filing shows second-quarter RoTCE of 13.0%, versus 8.7% a year earlier, while the first half of 2026 produced a 13.1% RoTCE. The new guidance therefore suggests management believes profitability can remain above the longer-term 11%-13% RoTCE range Citi established for 2027-28, despite additional investment spending.
Kiev.Victor / Shutterstock.com
The bullish argument is that Citigroup Inc. (NYSE:C) appears to be converting its multiyear restructuring into higher returns while simultaneously returning more capital to shareholders. The move from 8.7% RoTCE in the second quarter of 2025 to 13.0% in the second quarter of 2026 represents a substantial improvement in capital efficiency. Citi's efficiency ratio also improved to 57.4% from 62.7%, indicating that revenue growth is increasingly translating into operating leverage rather than being absorbed by expenses. That is particularly relevant because management now intends to spend another roughly $500 million on severance, marketing, and growth initiatives; if these investments produce the intended expansion in cards and wealth management, they could support revenue growth without derailing the profitability trajectory.
Capital returns provide another positive lever. Citi repurchased $13 billion of stock in 2025 and now expects to increase that amount, while its June 2026 CET1 ratio remained 12.78%, comfortably above its 11.6% standardized regulatory requirement. Buybacks can reduce tangible common equity and shares outstanding, potentially supporting both RoTCE and per-share earnings when executed below intrinsic value. Citi's tangible book value per share had already risen 7% year over year to $100.89 by June 30, 2026. The combination of higher operating profitability, shrinking share count, and improving capital efficiency strengthens the case for a valuation re-rating if Citi can sustain returns above 11%.
#year #management
3 days ago
Kimberly-Clark Corporation (NASDAQ:KMB) is preparing ***** et sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in Australia, where the deal received conditional approval after Kimberly-Clark agreed to divest Kenvue's Carefree and Stayfree brands.
The transaction is strategically important because it would create a consumer-health and personal-care company with approximately $32 billion of annual revenue and $7 billion of adjusted EBITDA. Kimberly-Clark Corporation (NASDAQ:KMB) expects about $1.9 billion of annual cost synergies and $500 million of revenue synergies, although it expects to invest roughly $2.5 billion in cash to achieve the cost savings. Therefore, the scale of any EU divestitures will be critical to determining whether Kimberly-Clark can retain the expected economic benefits of the deal.
The strongest bullish argument is that Kimberly-Clark Corporation (NASDAQ:KMB) is actively working toward a regulatory solution rather than allowing the EU review to threaten the transaction. If the company can satisfy regulators through limited ***** et sales, it could preserve the majority of Kenvue's revenue and earnings while moving ahead with the combination. The expected $1.9 billion in annual cost savings represents a substantial earnings opportunity relative to the combined company's roughly $7 billion adjusted EBITDA target, giving Kimberly-Clark significant potential to improve margins and cash generation after integration.
The Australian precedent also suggests that targeted divestitures could be sufficient to resolve competition concerns without materially undermining the broader deal. Securing EU approval by September 29 would be particularly positive because it would remove a major source of uncertainty and allow Kimberly-Clark Corporation (NASDAQ:KMB) to focus on integration and synergy execution. With Kenvue adding major brands across consumer health and personal care, successful completion could also broaden Kimberly-Clark's portfolio and reduce its reliance on its existing product categories.
The biggest risk is that the EU requires more substantial ***** et sales than Kimberly-Clark Corporation (NASDAQ:KMB) currently expects. Giving up attractive Kenvue brands or businesses in Europe could reduce the revenue and EBITDA acquired through the transaction, while Kimberly-Clark would still have to bear much of the financing, transaction, and integration burden. That could make the $40 billion purchase price less attractive on a risk-adjusted basis, particularly if the divested ***** ets are among Kenvue's stronger European businesses.
#revenue
The transaction is strategically important because it would create a consumer-health and personal-care company with approximately $32 billion of annual revenue and $7 billion of adjusted EBITDA. Kimberly-Clark Corporation (NASDAQ:KMB) expects about $1.9 billion of annual cost synergies and $500 million of revenue synergies, although it expects to invest roughly $2.5 billion in cash to achieve the cost savings. Therefore, the scale of any EU divestitures will be critical to determining whether Kimberly-Clark can retain the expected economic benefits of the deal.
The strongest bullish argument is that Kimberly-Clark Corporation (NASDAQ:KMB) is actively working toward a regulatory solution rather than allowing the EU review to threaten the transaction. If the company can satisfy regulators through limited ***** et sales, it could preserve the majority of Kenvue's revenue and earnings while moving ahead with the combination. The expected $1.9 billion in annual cost savings represents a substantial earnings opportunity relative to the combined company's roughly $7 billion adjusted EBITDA target, giving Kimberly-Clark significant potential to improve margins and cash generation after integration.
The Australian precedent also suggests that targeted divestitures could be sufficient to resolve competition concerns without materially undermining the broader deal. Securing EU approval by September 29 would be particularly positive because it would remove a major source of uncertainty and allow Kimberly-Clark Corporation (NASDAQ:KMB) to focus on integration and synergy execution. With Kenvue adding major brands across consumer health and personal care, successful completion could also broaden Kimberly-Clark's portfolio and reduce its reliance on its existing product categories.
The biggest risk is that the EU requires more substantial ***** et sales than Kimberly-Clark Corporation (NASDAQ:KMB) currently expects. Giving up attractive Kenvue brands or businesses in Europe could reduce the revenue and EBITDA acquired through the transaction, while Kimberly-Clark would still have to bear much of the financing, transaction, and integration burden. That could make the $40 billion purchase price less attractive on a risk-adjusted basis, particularly if the divested ***** ets are among Kenvue's stronger European businesses.
#revenue
3 days ago
Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use.
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and ***** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.
#weight
The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients, while Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month. Lilly's SEC filing says Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly's cardiometabolic revenue base.
The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients' preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Eli Lilly and Company (NYSE:LLY) is establishing meaningful competitive positioning before the oral GLP-1 market fully scales. Foundayo's formulation also has a practical advantage because it can be taken at any time of day without food or water restrictions, while Lilly's clinical data showed an average 27.3-pound, or 12.4%, weight reduction at the highest dose among patients who remained on treatment in ATTAIN-1.
The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. Lilly reported that in the ACHIEVE-3 trial, Foundayo produced a 57.1% greater relative reduction in A1C and a 73.6% greater relative reduction in body weight compared with oral semaglutide 14 mg. Lilly submitted Foundayo for type 2 diabetes in the U.S., EU, and ***** an, potentially expanding the addressable market beyond weight management.
The early oral-market traction also complements Eli Lilly and Company (NYSE:LLY)'s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year, while patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg. That suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly's broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.
#weight
3 days ago
A commonly used drug has been linked to a higher risk of death in a new study.
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
Severe side effects may include confusion, decreased consciousness or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
Older Adults Taking 5 Or More Prescription Drugs Face Higher Risk Of Death, Study Finds
New research suggests the medication may be ****** ociated with a higher risk of all-cause mortality.
#risk
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
Severe side effects may include confusion, decreased consciousness or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
Older Adults Taking 5 Or More Prescription Drugs Face Higher Risk Of Death, Study Finds
New research suggests the medication may be ****** ociated with a higher risk of all-cause mortality.
#risk
3 days ago
On September 14, Radiant Logistics (NYSEAMERICAN:RLGT) held its fourth fiscal quarter earnings call, and the headline numbers landed harder than a typical logistics update. Net income jumped 53.1% to $7.5 million for the quarter ended June 30, while revenue climbed 18.5% to $261.4 million. Look past that one quarter, though, and the picture gets more complicated, because full-year adjusted profitability actually fell. That gap between a blowout quarter and a softer year is what makes this name worth a closer look.
The fourth fiscal quarter was strong from top to bottom. Adjusted EBITDA rose 31.6% to $10.4 million, margin expanded 240 basis points to 15.5%, and adjusted net income climbed 34.5% to $7.4 million, all against organic revenue growth of 8%. Management credited the acceleration to US forwarding operations and international airfreight, including work supporting disaster relief after typhoon activity hit the Western Pacific earlier this year, plus airfreight demand tied to capital flows into global data center buildouts.
The balance sheet backs up the story. Radiant enters fiscal 2027 with zero net debt, $25.6 million in cash as of June 30, and a $200 million senior credit facility that was extended and restated in August, pushing maturity out to August 7, 2031, while its acquisition-focused accordion grew to $100 million from $75 million. On the domestic side, capacity has been exiting the truckload and intermodal markets, and spot rates and tender rejections moved higher late in the quarter. Radiant also launched a new independent agent program at Radiant Road & Rail during the quarter, extending its freight forwarding agent network into truck brokerage and intermodal, while Navegate is gaining traction, with one enterprise customer now managing more than 1,400 vendors on the platform.
The full-year numbers tell a different story than the quarter does. Revenue rose just 3.5% to $934.4 million from $902.7 million, a fraction of the fourth quarter's 18.5% pace, and full-year net income grew a modest 8.7% to $18.8 million. Full-year adjusted EBITDA actually fell 5.4% to $36.7 million from $38.8 million, and that figure included a $1.3 million First Brands adjustment. Strip that out and normalized adjusted EBITDA comes in at $35.4 million, an even steeper decline than the headline number suggests.
The operating backdrop stays complicated too. Ocean shipping routes remain disrupted by the closure of the Strait of Hormuz and continued Houthi activity affecting Suez Canal transits, keeping capacity tight on key trade lanes. US tariff policy is generating elevated IEEPA-related filing activity, and Canada put new retaliatory tariff measures into effect in early September, adding fresh complexity for shippers moving goods across that border. Management itself acknowledged that the domestic truck brokerage improvement seen late in the fourth quarter is not yet fully reflected in the reported results.
#million #quarter #revenue #fiscal
The fourth fiscal quarter was strong from top to bottom. Adjusted EBITDA rose 31.6% to $10.4 million, margin expanded 240 basis points to 15.5%, and adjusted net income climbed 34.5% to $7.4 million, all against organic revenue growth of 8%. Management credited the acceleration to US forwarding operations and international airfreight, including work supporting disaster relief after typhoon activity hit the Western Pacific earlier this year, plus airfreight demand tied to capital flows into global data center buildouts.
The balance sheet backs up the story. Radiant enters fiscal 2027 with zero net debt, $25.6 million in cash as of June 30, and a $200 million senior credit facility that was extended and restated in August, pushing maturity out to August 7, 2031, while its acquisition-focused accordion grew to $100 million from $75 million. On the domestic side, capacity has been exiting the truckload and intermodal markets, and spot rates and tender rejections moved higher late in the quarter. Radiant also launched a new independent agent program at Radiant Road & Rail during the quarter, extending its freight forwarding agent network into truck brokerage and intermodal, while Navegate is gaining traction, with one enterprise customer now managing more than 1,400 vendors on the platform.
The full-year numbers tell a different story than the quarter does. Revenue rose just 3.5% to $934.4 million from $902.7 million, a fraction of the fourth quarter's 18.5% pace, and full-year net income grew a modest 8.7% to $18.8 million. Full-year adjusted EBITDA actually fell 5.4% to $36.7 million from $38.8 million, and that figure included a $1.3 million First Brands adjustment. Strip that out and normalized adjusted EBITDA comes in at $35.4 million, an even steeper decline than the headline number suggests.
The operating backdrop stays complicated too. Ocean shipping routes remain disrupted by the closure of the Strait of Hormuz and continued Houthi activity affecting Suez Canal transits, keeping capacity tight on key trade lanes. US tariff policy is generating elevated IEEPA-related filing activity, and Canada put new retaliatory tariff measures into effect in early September, adding fresh complexity for shippers moving goods across that border. Management itself acknowledged that the domestic truck brokerage improvement seen late in the fourth quarter is not yet fully reflected in the reported results.
#million #quarter #revenue #fiscal
4 days ago
Alluvium ***** et Management, an ***** et management company, released its "Conventum – Alluvium Global Fund" second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined 1.4% in EUR terms, 2.2% in USD terms, and 3.9% in AUD terms. Portfolio results were mixed, with Alphabet benefiting from strong Cloud growth, while Robert Half, H&R Block, and other holdings posted solid gains. However, cable businesses and several healthcare and consumer holdings weighed on performance. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Conventum – Alluvium Global Fund highlighted Robert Half Inc. (NYSE:RHI). Robert Half Inc. (NYSE:RHI) is a leading staffing and consulting company. On September 15, 2026, Robert Half Inc. (NYSE:RHI) closed at $38.30 per share. Over the past month, Robert Half Inc. (NYSE:RHI) declined 12.03% and its shares gained 10.28% over the past 52 weeks. Robert Half Inc. (NYSE:RHI) has a market capitalization of $3.92 billion, and its stock has traded within a 52-week range of $21.83 and $46.70.
Conventum – Alluvium Global Fund stated the following regarding Robert Half Inc. (NYSE:RHI) in its Q2 2026 investor letter:
"We last wrote about Robert Half Inc. (NYSE:RHI) (up 23.5%) in our December report, where we mentioned that hindsight suggests our purchasing during price descents in May, August and October were mistakes. This remains the case - but less so. Our expectation that the recruitment / outplacement market will slowly recover, appears, going by Robert Half's recent results, to be bearing fruit. And management remain cautiously optimistic. We did not trade the stock. The Fund's position is now 2.7%."
Robert Half Inc. (NYSE:RHI) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Robert Half Inc. (NYSE:RHI) at the end of the second quarter which was 36 in the previous quarter. While we acknowledge the potential of Robert Half Inc. (NYSE:RHI) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#half #quarter #global #letter
In its second-quarter 2026 investor letter, Conventum – Alluvium Global Fund highlighted Robert Half Inc. (NYSE:RHI). Robert Half Inc. (NYSE:RHI) is a leading staffing and consulting company. On September 15, 2026, Robert Half Inc. (NYSE:RHI) closed at $38.30 per share. Over the past month, Robert Half Inc. (NYSE:RHI) declined 12.03% and its shares gained 10.28% over the past 52 weeks. Robert Half Inc. (NYSE:RHI) has a market capitalization of $3.92 billion, and its stock has traded within a 52-week range of $21.83 and $46.70.
Conventum – Alluvium Global Fund stated the following regarding Robert Half Inc. (NYSE:RHI) in its Q2 2026 investor letter:
"We last wrote about Robert Half Inc. (NYSE:RHI) (up 23.5%) in our December report, where we mentioned that hindsight suggests our purchasing during price descents in May, August and October were mistakes. This remains the case - but less so. Our expectation that the recruitment / outplacement market will slowly recover, appears, going by Robert Half's recent results, to be bearing fruit. And management remain cautiously optimistic. We did not trade the stock. The Fund's position is now 2.7%."
Robert Half Inc. (NYSE:RHI) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Robert Half Inc. (NYSE:RHI) at the end of the second quarter which was 36 in the previous quarter. While we acknowledge the potential of Robert Half Inc. (NYSE:RHI) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#half #quarter #global #letter
5 days ago
Apple (AAPL) recently decided to buy startup Sonera, which has reportedly developed a neural-data technology tool. The move could boost Apple stock within the next few years and bodes well for the company's long-term outlook. In the medium term, however, AAPL stock is unlikely to surpass the returns of the Nasdaq-100 by a significant margin, as the company continues to face multiple, negative catalysts. Weaker-than-expected revenue-growth guidance for the current quarter also suggests that these factors are beginning to weigh on Apple's performance. Let's take a closer look.
Earlier this year, Apple agreed to buy California-based startup called Sonera, which the European Commission disclosed on Sept. 8. The startup reportedly utilizes "breakthrough sensing technology" which allows it to ***** yze human brains without making direct contact with individuals' bodies.
Dear ***** eX Stock Fans, Mark Your Calendars for September 21
How to Play IBM Stock as It Teams Up with NASA to Launch a New Open-Source Model
GF Securities Says NAND Prices May Stabilize Later This Year. What This Means for Sandisk Stock.
#Apple
Earlier this year, Apple agreed to buy California-based startup called Sonera, which the European Commission disclosed on Sept. 8. The startup reportedly utilizes "breakthrough sensing technology" which allows it to ***** yze human brains without making direct contact with individuals' bodies.
Dear ***** eX Stock Fans, Mark Your Calendars for September 21
How to Play IBM Stock as It Teams Up with NASA to Launch a New Open-Source Model
GF Securities Says NAND Prices May Stabilize Later This Year. What This Means for Sandisk Stock.
#Apple
5 days ago
On August 4, Willis Lease Finance Corporation (NASDAQ:WLFC) reported second-quarter results that pulled in two directions at once. The lessor of commercial aircraft engines grew its operating business at a healthy clip, yet net income fell by more than half, a split that makes this quarter harder to read than the headline suggests.
Income from operations climbed 20.2% to $34.0 million in the quarter ended June 30, 2026, and the engine underneath that number is lease rent revenue, which rose 6.7% to $77.1 million as the average size of Willis Lease's portfolio expanded from a year earlier. Over the first six months of 2026, lease rent revenue is up 10.4% to $154.5 million, a steadier pace than the quarterly figure alone implies.
The company's trading business added to that. Willis Lease booked a $32.0 million gain on the sale of leased equipment, up 16.2%, after selling 21 engines and other parts and equipment during the quarter, compared with 14 engines and two airframes a year earlier. That kind of turnover matters for a leasing company, since selling ****** ets at a gain confirms that engine values in the market are holding up.
The bigger story sits in how Willis Lease is expanding beyond its own balance sheet. ****** ets under management, which folds in the company's on-balance-sheet fleet along with its Willis Aviation Capital business, grew 21% year over year to $4.4 billion. CEO Austin C. Willis tied that growth directly to building out Willis Aviation Capital, and the fee income backs that up: management and advisory fees jumped 113.4% to $5.5 million in the quarter and 194.9% to $13.4 million over six months. Two new investment fund partnerships, one with Liberty Mutual Investments that began operating in March 2026 and one with Blackstone Credit & Insurance that started in April 2026, are the mechanics behind that shift toward managing other people's capital rather than only deploying its own.
Net income attributable to common shareholders fell 51.2% to $28.7 million, and diluted earnings per share dropped from $2.81 to $1.31. Some of that gap traces to a tough comparison rather than a weaker quarter, since the second quarter of 2025 included a $43.0 million gain from the sale of the BAML business that had no counterpart this year. Willis Lease also recognized a $5.4 million loss on debt extinguishment in the quarter, and $12.4 million over six months, a cost tied to refinancing that simply was not there in 2025.
#lease #capital #months
Income from operations climbed 20.2% to $34.0 million in the quarter ended June 30, 2026, and the engine underneath that number is lease rent revenue, which rose 6.7% to $77.1 million as the average size of Willis Lease's portfolio expanded from a year earlier. Over the first six months of 2026, lease rent revenue is up 10.4% to $154.5 million, a steadier pace than the quarterly figure alone implies.
The company's trading business added to that. Willis Lease booked a $32.0 million gain on the sale of leased equipment, up 16.2%, after selling 21 engines and other parts and equipment during the quarter, compared with 14 engines and two airframes a year earlier. That kind of turnover matters for a leasing company, since selling ****** ets at a gain confirms that engine values in the market are holding up.
The bigger story sits in how Willis Lease is expanding beyond its own balance sheet. ****** ets under management, which folds in the company's on-balance-sheet fleet along with its Willis Aviation Capital business, grew 21% year over year to $4.4 billion. CEO Austin C. Willis tied that growth directly to building out Willis Aviation Capital, and the fee income backs that up: management and advisory fees jumped 113.4% to $5.5 million in the quarter and 194.9% to $13.4 million over six months. Two new investment fund partnerships, one with Liberty Mutual Investments that began operating in March 2026 and one with Blackstone Credit & Insurance that started in April 2026, are the mechanics behind that shift toward managing other people's capital rather than only deploying its own.
Net income attributable to common shareholders fell 51.2% to $28.7 million, and diluted earnings per share dropped from $2.81 to $1.31. Some of that gap traces to a tough comparison rather than a weaker quarter, since the second quarter of 2025 included a $43.0 million gain from the sale of the BAML business that had no counterpart this year. Willis Lease also recognized a $5.4 million loss on debt extinguishment in the quarter, and $12.4 million over six months, a cost tied to refinancing that simply was not there in 2025.
#lease #capital #months
5 days ago
On September 10, IBEX Limited (NASDAQ:IBEX) held its fourth-quarter and full fiscal year 2026 earnings call, and the numbers backed up a message management has been building toward for months. The company posted record full-year revenue, adjusted EBITDA, and free cash flow, all while pitching itself as a business that has flipped the AI narrative in its favor rather than becoming its next casualty. For a sector that has spent the last two years bracing for automation to gut it, that is a notable claim to back with actual client wins.
Full-year revenue hit $644.1 million, up 15.4% organically, and fourth-quarter revenue reached $164.3 million, up 11.6% from a year earlier. That marked the sixth straight quarter of double-digit growth, a streak that suggests the momentum is not a one-off. HealthTech led the charge, climbing 38.5% to $114 million for the year and blowing past the $100 million target management had set for the segment, driven largely by demand from large insurance payers. Technology grew 27.4% in the quarter, while travel and logistics added 17.8%, helped by a new AI agent partnership with Philippine Airlines.
That Philippine Airlines deal is the clearest evidence that IBEX's Sierra AI partnership, formalized in January and announced publicly in May, is more than a slide in an investor deck. During the proof of concept, the AI agent handled interactions in English, Tagalog, and Taglish, hit resolution rates above 20%, and scored a 4.7 out of 5.0 on customer satisfaction, on par with human agents. A separate deployment for BJ's Wholesale pushed resolution rates above 40% and matched that same satisfaction score, beating the marks the client's prior BPO vendor had put up with human agents alone. The company added 17 new trophy logo clients across the year, and its top five clients now make up 33% of revenue, down from 36%, a sign the business is not leaning on a shrinking handful of accounts to carry it.
Not every line moved in the right direction. Fourth quarter GAAP net income slipped to $8.7 million from $9.6 million a year earlier, and diluted EPS fell to $0.59 from $0.66. Management pointed to training costs tied to all those new client wins, a temporary hit from shifting work out of nearshore centers into offshore ones, and higher fuel prices hitting utility and transportation costs, particularly offshore. Adjusted EBITDA margin for the quarter slipped to 12.3% from 13.9%, the same set of pressures showing up in the profitability line rather than just net income.
#revenue #fourth
Full-year revenue hit $644.1 million, up 15.4% organically, and fourth-quarter revenue reached $164.3 million, up 11.6% from a year earlier. That marked the sixth straight quarter of double-digit growth, a streak that suggests the momentum is not a one-off. HealthTech led the charge, climbing 38.5% to $114 million for the year and blowing past the $100 million target management had set for the segment, driven largely by demand from large insurance payers. Technology grew 27.4% in the quarter, while travel and logistics added 17.8%, helped by a new AI agent partnership with Philippine Airlines.
That Philippine Airlines deal is the clearest evidence that IBEX's Sierra AI partnership, formalized in January and announced publicly in May, is more than a slide in an investor deck. During the proof of concept, the AI agent handled interactions in English, Tagalog, and Taglish, hit resolution rates above 20%, and scored a 4.7 out of 5.0 on customer satisfaction, on par with human agents. A separate deployment for BJ's Wholesale pushed resolution rates above 40% and matched that same satisfaction score, beating the marks the client's prior BPO vendor had put up with human agents alone. The company added 17 new trophy logo clients across the year, and its top five clients now make up 33% of revenue, down from 36%, a sign the business is not leaning on a shrinking handful of accounts to carry it.
Not every line moved in the right direction. Fourth quarter GAAP net income slipped to $8.7 million from $9.6 million a year earlier, and diluted EPS fell to $0.59 from $0.66. Management pointed to training costs tied to all those new client wins, a temporary hit from shifting work out of nearshore centers into offshore ones, and higher fuel prices hitting utility and transportation costs, particularly offshore. Adjusted EBITDA margin for the quarter slipped to 12.3% from 13.9%, the same set of pressures showing up in the profitability line rather than just net income.
#revenue #fourth
5 days ago
Jennifer Aniston's love life has long fascinated fans, but the latest insight into her relationship with Jim Curtis suggests their connection developed in a very different way than many might expect.
Rather than starting with instant romance, the pair built a foundation away from the spotlight, letting a friendship grow before taking things further.
According to Curtis, that slower path ultimately changed the way he approached love altogether.
ZUMAPRESS.com / MEGA
Long before Jennifer Aniston and Jim Curtis became a couple, they spent months getting to know each other as friends.
#rather #aniston #life
Rather than starting with instant romance, the pair built a foundation away from the spotlight, letting a friendship grow before taking things further.
According to Curtis, that slower path ultimately changed the way he approached love altogether.
ZUMAPRESS.com / MEGA
Long before Jennifer Aniston and Jim Curtis became a couple, they spent months getting to know each other as friends.
#rather #aniston #life
5 days ago
Marriott International, Inc. (NASDAQ:MAR)'s Middle East business showed a meaningful improvement in July, with revenue per available room (RevPAR) declining 12% year over year, a sharp improvement from the 43% decline in the second quarter. The improvement came despite continued regional conflict, suggesting that demand is proving more resilient than initially feared. More importantly, Marriott's global business remains strong: global room revenue increased 7% in July, with the U.S. and Canada up 8%.
However, the Middle East remains a risk to Marriott International, Inc. (NASDAQ:MAR)'s growth strategy. The region represents only about 3% of Marriott's global fees but 6% of its development pipeline, meaning prolonged conflict can have an outsized impact on future hotel openings. Supply-chain disruptions and restricted capital flows have already delayed projects, pushing Marriott toward the lower end of its full-year net unit growth target.
The biggest positive is that the Middle East headwind appears to be easing faster than expected. Moving from a 43% RevPAR decline in the second quarter to just 12% in July suggests travel demand can recover even as geopolitical risks remain elevated. If the conflict stabilizes, Marriott International, Inc. (NASDAQ:MAR) could see a relatively quick rebound in regional occupancy and room rates.
More importantly, the Middle East is not large enough to overwhelm Marriott's broader global performance. The company generated a 7% increase in global room revenue in July, while U.S. and Canadian room revenue rose 8%. RevPAR growth was also broad-based across luxury, premium/select and mid-scale brands, suggesting that Marriott's strength is not dependent solely on wealthy travelers.
Marriott also benefits from an ***** et-light, fee-driven model, meaning stronger hotel demand can translate into attractive cash generation without requiring the company to own most of the underlying properties. Barron's has highlighted the resilience of this model, alongside the strength of Marriott Bonvoy and additional growth opportunities from its credit-card partnerships.
#marriott #middle #room
However, the Middle East remains a risk to Marriott International, Inc. (NASDAQ:MAR)'s growth strategy. The region represents only about 3% of Marriott's global fees but 6% of its development pipeline, meaning prolonged conflict can have an outsized impact on future hotel openings. Supply-chain disruptions and restricted capital flows have already delayed projects, pushing Marriott toward the lower end of its full-year net unit growth target.
The biggest positive is that the Middle East headwind appears to be easing faster than expected. Moving from a 43% RevPAR decline in the second quarter to just 12% in July suggests travel demand can recover even as geopolitical risks remain elevated. If the conflict stabilizes, Marriott International, Inc. (NASDAQ:MAR) could see a relatively quick rebound in regional occupancy and room rates.
More importantly, the Middle East is not large enough to overwhelm Marriott's broader global performance. The company generated a 7% increase in global room revenue in July, while U.S. and Canadian room revenue rose 8%. RevPAR growth was also broad-based across luxury, premium/select and mid-scale brands, suggesting that Marriott's strength is not dependent solely on wealthy travelers.
Marriott also benefits from an ***** et-light, fee-driven model, meaning stronger hotel demand can translate into attractive cash generation without requiring the company to own most of the underlying properties. Barron's has highlighted the resilience of this model, alongside the strength of Marriott Bonvoy and additional growth opportunities from its credit-card partnerships.
#marriott #middle #room
7 days ago
Solaris Energy Infrastructure, Inc. (NYSE:SEI), traditionally known as an oil and gas field services and solutions company, has been increasingly shifting toward the data center market. On September 8, the company provided an update to its guidance ranges, which suggests that this shift is working.
The company lifted its adjusted EBITDA guidance for the third and fourth quarters of 2026 and provided its initial outlook for the first quarter of 2027. The company said that the updated expectations reflect stronger contributions from its core power services business, along with better-than-expected performance from recently acquired businesses. Solaris Energy Infrastructure, Inc. (NYSE:SEI) now expects Q3 2026 adjusted EBITDA of $110 million to $130 million, up from its previous range of $90 million to $105 million. At the midpoint, that represents a 23% increase.
For Q4 2026, the company raised its guidance to $145 million to $180 million from $100 million to $120 million, a 48% increase at the midpoint. The company also provided initial Q1 2027 adjusted EBITDA guidance of $200 million to $240 million.
Investors responded positively to the update as the stock rallied following the announcement. Solaris Energy Infrastructure, Inc. (NYSE:SEI) has returned about 150% over the past 12 months. As of September 8, the stock was up more than 25% year to date, compared with a 12% gain for the S&P 500.
The guidance update follows the company's September 2 announcement of its acquisition of Omega Foundation Services, a leader in the specialized engineering, procurement and construction industry with expertise in heavy civil construction across several end markets, including large-scale data centers.
#energy #Services
The company lifted its adjusted EBITDA guidance for the third and fourth quarters of 2026 and provided its initial outlook for the first quarter of 2027. The company said that the updated expectations reflect stronger contributions from its core power services business, along with better-than-expected performance from recently acquired businesses. Solaris Energy Infrastructure, Inc. (NYSE:SEI) now expects Q3 2026 adjusted EBITDA of $110 million to $130 million, up from its previous range of $90 million to $105 million. At the midpoint, that represents a 23% increase.
For Q4 2026, the company raised its guidance to $145 million to $180 million from $100 million to $120 million, a 48% increase at the midpoint. The company also provided initial Q1 2027 adjusted EBITDA guidance of $200 million to $240 million.
Investors responded positively to the update as the stock rallied following the announcement. Solaris Energy Infrastructure, Inc. (NYSE:SEI) has returned about 150% over the past 12 months. As of September 8, the stock was up more than 25% year to date, compared with a 12% gain for the S&P 500.
The guidance update follows the company's September 2 announcement of its acquisition of Omega Foundation Services, a leader in the specialized engineering, procurement and construction industry with expertise in heavy civil construction across several end markets, including large-scale data centers.
#energy #Services
7 days ago
For most of your adult life, you have decided which card comes out of your wallet. Maybe it is the one with the best cashback. Maybe it is the one on top.
That decision is starting to move to software.
More than one in 10 online shoppers will routinely use AI agents to shop and pay by 2030, according to a report published Sept. 8, 2026 by Mastercard (MA). That works out to more than 300 million people worldwide.
The number reads like a distant projection. Recent US data suggests the behavior is already further along than that.
The report, ******* led "A short history of the future of shopping and payments," pairs original consumer research with predictions from four futurists in the US, Europe and Asia, according to Mastercard.
#maybe
That decision is starting to move to software.
More than one in 10 online shoppers will routinely use AI agents to shop and pay by 2030, according to a report published Sept. 8, 2026 by Mastercard (MA). That works out to more than 300 million people worldwide.
The number reads like a distant projection. Recent US data suggests the behavior is already further along than that.
The report, ******* led "A short history of the future of shopping and payments," pairs original consumer research with predictions from four futurists in the US, Europe and Asia, according to Mastercard.
#maybe
